Condition: Recurrent Multiple Myeloma · Refractory Multiple Myeloma · Sponsor: National Cancer Institute (NCI)
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with relapsed or refractory multiple myeloma.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital in Arizona | Phoenix, Arizona, United States | Recruiting |
| Smilow Cancer Hospital-Derby Care Center | Derby, Connecticut, United States | Recruiting |
| Smilow Cancer Hospital Care Center - Guilford | Guilford, Connecticut, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| Yale-New Haven Hospital North Haven Medical Center | North Haven, Connecticut, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Suspended |
| University of Kansas Cancer Center | Kansas City, Kansas, United States | Recruiting |
| University of Kansas Cancer Center-Overland Park | Overland Park, Kansas, United States | Recruiting |
| University of Kansas Hospital-Westwood Cancer Center | Westwood, Kansas, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06465316